4-(2-[2-(2(<i>R</i>)-Methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and Related 2-Aminoethylbenzofuran H<sub>3</sub> Receptor Antagonists Potently Enhance Cognition and Attention

Marlon Cowart(Abbott Fund), Ramin Faghih(Abbott Fund), Michael P. Curtis(Abbott Fund), Gregory A. Gfesser(Abbott Fund), Youssef L. Bennani(Abbott Fund), Lawrence A. Black(Abbott Fund), Liping Pan(Abbott Fund), Kennan C. Marsh(Abbott Fund), James P. Sullivan(Abbott Fund), Timothy A. Esbenshade(Abbott Fund), Gerard B. Fox(Abbott Fund), Arthur A. Hancock(Abbott Fund)
Journal of Medicinal Chemistry
December 13, 2004
Cited by 122Open Access
Full Text

Abstract

H(3) receptor antagonists based on a 2-aminoethylbenzofuran skeleton have been discovered, which are potent in vitro at human and rat H(3) receptors, with K(i) values of 0.1-5.8 nM. Analogues were discovered with potent (0.01-1 mg/kg) cognition and attention enhancing properties in animal models. One compound in particular, 4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile (ABT-239), combined potent and selective H(3) receptor antagonism and excellent pharmacokinetic and metabolic properties across species, with full efficacy in two behavioral models: a five-trial inhibitory avoidance acquisition model in rat pups at 0.1 mg/kg and a social recognition memory model in adult rats at 0.01 mg/kg. Furthermore, this compound did not stimulate locomotor activity and showed high selectivity for the induction of behavioral efficacy versus central nervous system based side effects. The potency and selectivity of this compound and of analogues from this class support the potential of H(3) receptor antagonists for the treatment of cognitive dysfunction.


Related Papers

No related papers found

Powered by citation graph analysis